钙通道阻滞剂在联合降压中的作用

Role of calcium-channel blocker in antihypertensive combination

钙通道阻滞剂(CCB)已经成为最广泛使用的降压药物,并可以很好地与其他各类降压药物联合应用。二氢吡啶类CCB与血管紧张素转换酶(ACE)抑制剂或血管紧张素受体拮抗剂(ARB)的联合在多项大型临床研究中显示出优越性。氨氯地平和拉西地平等第三代CCB半衰期更长、副反应更少、抗动脉粥样硬化等心血管保护作用证据更多,特别适合于老年单纯收缩期高血压、伴冠心病或颈动脉粥样硬化的高血压患者。

Calcium-channel blocker（CCB） has become a widely used antihypertensive. It can be used with other antihypertensives with satisfactory effect and safety. Many large clinical trials have showed that dihydropyridines is superior in combination with ACE inhibitor or ARB. Class ⅢCCB such as amlodipine and lacidipine have longer halflife, less side effect and more potent anti-artherosclerosis and cardiovascular protection effects, especially in hypertension patients with old age,isolated systolic hypertension, coronary heart diseases or carotid artery artherosclerosis.